Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atea Pharmaceuticals Inc AVIR

Healthcare
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is... see more

Recent & Breaking News (NDAQ:AVIR)

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021

GlobeNewswire March 23, 2021

Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections

GlobeNewswire March 6, 2021

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

GlobeNewswire February 19, 2021

Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

GlobeNewswire February 8, 2021

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting

GlobeNewswire February 4, 2021

Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications

GlobeNewswire January 19, 2021

Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 21, 2020

Atea Pharmaceuticals Added to Russell 2000 Index

GlobeNewswire December 18, 2020

Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

GlobeNewswire November 25, 2020

Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan

GlobeNewswire November 6, 2020

Atea Pharmaceuticals Announces Closing of Initial Public Offering

GlobeNewswire November 3, 2020

Atea Pharmaceuticals Announces Pricing of Initial Public Offering

GlobeNewswire October 29, 2020

Vaxart Provides Merger Update

Business Wire February 9, 2018

CAS Group Supports Improved Vaxart Merger and Enters Into Agreement With Aviragen

PR Newswire February 9, 2018

Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms

GlobeNewswire February 9, 2018

Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders

GlobeNewswire February 7, 2018

Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018

GlobeNewswire February 6, 2018

Vaxart Issues Statement Regarding Proposed Merger With Aviragen

Business Wire January 31, 2018

Aviragen Provides New Information Supporting Vote FOR Vaxart Merger

GlobeNewswire January 31, 2018

CAS Group Announces Glass Lewis Recommendation That Aviragen Stockholders Vote AGAINST Merger and Emphasizes Value of Teslexivir (BTA074) Program

PR Newswire January 31, 2018